All Posts:Memory Disorders Program

• Georgetown Study Explores THC/CBD Combination to Reduce Dementia-related Agitation at the End of Life

  In a first-of-its-kind clinical trial, the Georgetown University Medical Center Memory Disorders Program will study the effects of an oral drug called T2:C100, which is comprised of two components found in marijuana — THC and CBD. The goal of the study is to investigate its potential to decrease agitation experienced by those with dementia at the end of life.

  Category: News Release Tags: Alzheimer's disease, brain, clinical trials, dementia, end of life care, Memory Disorders Program, mind, palliative care, research